Previous 10 | Next 10 |
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
– TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells – TransCon IL-2 β/γ administer...
COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m. Eastern Time. The event will feature pr...
COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host informational booth and events, at ECE 2023, the European Congress of Endo...
2023-05-11 12:29:00 ET Summary In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1 2023, thanks to the German price approval for Raya...
2023-05-04 16:20:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2023, Baron Health Care Fund declined 3.69%, compared w...
COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the BofA Se...
2023-05-02 14:38:18 ET Summary Ascendis reported strong Q1 2023 Skytrofa revenue (EUR 31.6m) and 2023 guidance (EUR 150-160m), but the stock traded down likely due to the FDA's CRL on its PTH drug for manufacturing concerns. The FDA did not request additional clinical data, implyi...
2023-05-01 11:45:59 ET Shares of Ascendis Pharma (NASDAQ: ASND) rose more than 19% Monday morning after the Danish pharmaceutical company received a critical response letter (CRL) from the Food and Drug Administration (FDA). The biotech company specializes in therapies to tr...
2023-05-01 10:03:58 ET Gainers: Nano-X Imaging ( NNOX ) +53% . Meihua International Medical Technologies ( MHUA ) +34% . Minerva Neurosciences ( NERV ) +27% . Apollomics ( APLM ) +24% . Ascendis Pharma ( ASND ) +19% . ...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...